Abstract
In the recent decades rheumatology has been witnessing the marked progress associated with introduction into clinical practice of gene engineering biological drugs. At the same time use of these drugs is associated with the increasing risk of development of infections of various nature and localization including opportunistic (invasive mycoses, pneumocystic pneumonia etc.) as well as the increased risk of reactivation of the latent infection, tuberculosis (TB), first of all. In addition to this, cases of grave infections (pneumonia, sepsis, bacterial arthritis, skin and soft tissue lesions etc.) are registered, including – with letal outcome. This review analyzes the literature data predominantly of the recent 5 years relating to frequency and localization of infections in rheumatoid arthritis patients at therapy by various GIBD. The importance of various infections (TB, pneumonias, chronic viral hepatitis, herpes-viral infections etc.) in the tactics of the specified patients follow-up is characterized. The necessity of a wider use of immunization by various vaccines (first of all, pneumococcal and anti-flu ones) of patients with autoimmune inflammatory rheumatic diseases is underlined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
